The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Considerations in Demonstrating Interchangeability With a Reference Product: Guidance for Industry [Docket No. FDA-2017-D-0154]” as published in the Federal Register on January 18, 2017.
All of the undersigned groups share the FDA's deep commitment to the development of a robust biosimilars market for patients, and greatly appreciate all the work the agency has done in creating certainty around the approval pathway created by the Biologics Price Competition and Innovation Act (BPCIA), including the long anticipated proposed guidance detailing the requirements of obtaining an interchangeability designation for a biosimilar.
The Academy of Managed Care Pharmacy (AMCP) is writing to express concerns with specific provisions of Substitute Bill No.7118 regarding the regulation of biological products and the substitution of interchangeable biological products when dispensed by pharmacists.
The Academy of Managed Care Pharmacy (AMCP) thanks the Washington Department of Labor & Industries for the opportunity to provide comments in response to CR-102 Proposed Language on Interchangeable Biologics, the Prescription Drug Program and Therapeutic Interchange.
In support of House Bill No. 628, AMCP believes that a pilot medication therapy management (MTM) program for patients in the TennCare program will lead to higher quality care for those patients.
The Academy of Managed Care Pharmacy (AMCP) urges you to support Senate Bill No. 398, which would establish a Medication Therapy Management (MTM) pilot program as a component of the TennCare program.
The Academy of Managed Care Pharmacy (AMCP) urges you to support House Bill No. 628, which would establish a Medication Therapy Management (MTM) pilot program as a component of the TennCare program. MTM services have demonstrated success for Medicare Part D beneficiaries by improving patient outcomes while decreasing overall health care costs, and AMCP strongly supports the expansion of MTM services for other patient groups including Medicaid beneficiaries.